Glatiramer Acetate Treatment Normalizes Deregulated microRNA Expression in Relapsing Remitting Multiple Sclerosis | Zendy

Anne Waschbisch | Zendy; Monika Atiya | Zendy; Ralf A. Linker | Zendy; Sergej Potapov | Zendy; Stefan Schwab | Zendy; Tobias Derfuß | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Glatiramer Acetate Treatment Normalizes Deregulated microRNA Expression in Relapsing Remitting Multiple Sclerosis

Author(s) -

Anne Waschbisch,

Monika Atiya,

Ralf A. Linker,

Sergej Potapov,

Stefan Schwab,

Tobias Derfuß

Publication year - 2011

Publication title -

plos one

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.99

H-Index - 332

ISSN - 1932-6203

DOI - 10.1371/journal.pone.0024604

Subject(s) - glatiramer acetate , multiple sclerosis , microrna , peripheral blood mononuclear cell , medicine , immune system , relapsing remitting , immunology , biology , in vitro , gene , biochemistry

The expression of selected microRNAs (miRNAs) known to be involved in the regulation of immune responses was analyzed in 74 patients with relapsing remitting multiple sclerosis (RRMS) and 32 healthy controls. Four miRNAs (miR-326, miR-155, miR-146a, miR-142-3p) were aberrantly expressed in peripheral blood mononuclear cells from RRMS patients compared to controls. Although expression of these selected miRNAs did not differ between treatment-naïve (n = 36) and interferon-beta treated RRMS patients (n = 18), expression of miR-146a and miR-142-3p was significantly lower in glatiramer acetate (GA) treated RRMS patients (n = 20) suggesting that GA, at least in part, restores the expression of deregulated miRNAs in MS.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research